Delivers net sales of $5.0 billion on 1 percent organic sales
growth
Results and outlook reflect strong in-market
execution, effective cost management and productivity
DALLAS, Oct. 22,
2024 /PRNewswire/ -- Kimberly-Clark Corporation
(NYSE: KMB) today reported third quarter 2024 results driven
by market-leading consumption growth from pioneering, innovative
new products, and leveraging sustained productivity momentum.
"Our third quarter results reflect strong execution across the
business as we transform our organization," said Kimberly-Clark
Chairman and CEO, Mike Hsu. "I'm
very proud of our teams' ability to deliver organic
top-and-bottom-line growth, driven by market share gains and
improved productivity, even against the backdrop of a dynamic
consumer environment."
Hsu continued, "With our Powering Care strategy in full swing,
we are accelerating our innovation pipeline and reducing costs to
deliver higher-quality consumer solutions for every price point,
and simplifying our operational structure so that we can be faster
and more responsive in our markets. We are on track to deliver
strong operating profit, margin, and EPS growth in 2024 while
investing to maintain our business momentum into 2025."
Quarter Highlights
- Net sales of $5.0 billion were
down 4 percent, with organic sales growth of 1 percent versus the
prior year.
- Reported gross margin was 36.0 percent, adjusted gross margin
was 36.7 percent, up 90 basis points versus the prior year, driven
by strong gross productivity gains.
- Diluted earnings per share were $2.69; adjusted earnings per share were
$1.83, up 5 percent versus prior year
including a $0.07 year-on-year
headwind from currency translation.
Third Quarter 2024 Results
Third quarter sales of $5.0
billion were 4 percent lower than the prior-year
period, including negative impacts of approximately 3 percent
from foreign currency translation and approximately 1 percent from
the divestiture of the K-C Professional Personal Protective
Equipment (PPE) business completed in July
2024. Organic sales increased 1 percent, driven by a 1
percent increase in price while volume and mix were in line with a
year ago. Price-led gains reflected necessary pricing actions to
address higher local costs in hyperinflationary economies, mainly
in Argentina. Volume and mix were
positive in Developed Markets (representing Australia, South
Korea and Western/Central
Europe) offset by a decline in North America while volumes in Developing and
Emerging (D&E) markets were in line with year ago.
In North America, organic sales
decreased 1 percent versus the prior year, driven by a 3
percent decline in K-C Professional and 1 percent in Consumer
Tissue while Personal Care was in line with year ago.
In D&E markets, organic sales rose 8 percent reflecting
pricing gains primarily in hyperinflationary economies.
Organic sales for Developed Markets were 2 percent lower, driven by
lower pricing that primarily reflected comparisons with temporary,
energy surcharge-related price increases in Western Europe in the prior-year period
partially offset by low single digit volume led gains.
Third quarter operating profit was $1.2
billion, including $565
million of gains from the divestiture of the PPE business.
Adjusted operating profit increased by 5 percent despite an
unfavorable impact of 4 percentage points from currency translation
that was primarily driven by hyperinflationary economies. Excluding
currency impacts, growth in adjusted operating profit reflected
gross productivity gains, relatively neutral pricing net of
cost inflation, supply chain related investments, as well as
planned increases in marketing, research and general expenses.
Net interest expense was $49
million versus $56 million in
the prior-year.
The third quarter effective tax rate was 20.5 percent. On an
adjusted basis, the effective rate in the third quarter was 22.7
percent compared to 22.5 percent in the prior year.
Net income of equity companies was $48 million compared to
$50 million in the prior-year
period.
Diluted EPS was $2.69 on a
reported basis and included a positive $1.34 impact from the sale of the PPE business, a
negative $0.31 impact from costs
related to the company's Transformation Initiative and a
negative $0.17 impact from impairment
of intangible assets. On an adjusted basis, EPS increased 5 percent
to $1.83, driven primarily by the 5
percent increase in adjusted operating profit.
Year-To-Date Results
For the first nine months of the year, sales of $15.1 billion decreased 2 percent including
negative impacts of approximately 4 percent from foreign
currency translation and approximately 1 percent from divestitures.
Organic sales grew 4 percent, driven by an approximately 2 percent
increase in price, primarily in hyperinflationary economies, 1
percent from favorable product mix and 1 percent increase in
volume.
Year-to-date operating profit was $2.7
billion, including $565
million of gains from the divestiture of the PPE business,
and $359 million of costs related to
the company's transformation initiative.
Year-to-date adjusted operating profit was $2.6 billion versus $2.3
billion in the prior year. This was an increase of 12
percent versus prior year including an unfavorable impact of 8
percentage points from currency translation, primarily driven by
hyperinflationary economies. Excluding currency impacts, the growth
in adjusted operating profit was driven by a combination of organic
growth and strong productivity savings that were partially offset
by input cost inflation, primarily in D&E markets, supply chain
related investments, impact of divestitures and planned increases
in marketing, research and general expenses.
Through the first nine months of the year, diluted earnings per
share were $6.21 in 2024 compared to
$3.70 last year. Year-to-date
adjusted earnings per share were $5.80 compared to $5.06 last year.
Business Segment Net Sales Results
Q3 change vs year ago (%)
|
|
Volume
|
|
Mix/Other
|
|
Net
Price
|
|
Divestitures
and
Business
Exits(a)
|
|
Currency
Translation
|
|
Total(b)
|
|
Organic(c)
|
Personal Care
|
|
—
|
|
1
|
|
3
|
|
—
|
|
(6)
|
|
(2)
|
|
3
|
North
America
|
|
—
|
|
1
|
|
(1)
|
|
—
|
|
—
|
|
(1)
|
|
—
|
D&E
Markets
|
|
—
|
|
—
|
|
11
|
|
—
|
|
(15)
|
|
(4)
|
|
11
|
Developed
Markets
|
|
—
|
|
1
|
|
(4)
|
|
—
|
|
(1)
|
|
(4)
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Tissue
|
|
—
|
|
—
|
|
(1)
|
|
—
|
|
—
|
|
(2)
|
|
(1)
|
North
America
|
|
(2)
|
|
—
|
|
1
|
|
—
|
|
—
|
|
(1)
|
|
(1)
|
D&E
Markets
|
|
4
|
|
—
|
|
(4)
|
|
(1)
|
|
(1)
|
|
(3)
|
|
(1)
|
Developed
Markets
|
|
3
|
|
—
|
|
(5)
|
|
—
|
|
(1)
|
|
(3)
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
K-C Professional
|
|
(1)
|
|
—
|
|
(1)
|
|
(7)
|
|
(2)
|
|
(10)
|
|
(1)
|
North
America
|
|
(2)
|
|
—
|
|
(1)
|
|
(9)
|
|
—
|
|
(11)
|
|
(3)
|
D&E
Markets
|
|
(6)
|
|
1
|
|
9
|
|
(4)
|
|
(9)
|
|
(9)
|
|
4
|
Developed
Markets
|
|
7
|
|
—
|
|
(8)
|
|
(6)
|
|
(1)
|
|
(7)
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
|
|
—
|
|
—
|
|
1
|
|
(1)
|
|
(3)
|
|
(4)
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YTD change vs year ago (%)
|
|
Volume
|
|
Mix/Other
|
|
Net
Price
|
|
Divestitures
and
Business
Exits(a)
|
|
Currency
Translation
|
|
Total(b)
|
|
Organic(c)
|
Personal Care
|
|
1
|
|
1
|
|
5
|
|
—
|
|
(8)
|
|
(1)
|
|
7
|
North
America
|
|
2
|
|
1
|
|
—
|
|
—
|
|
—
|
|
2
|
|
2
|
D&E
Markets
|
|
2
|
|
1
|
|
14
|
|
—
|
|
(20)
|
|
(3)
|
|
17
|
Developed
Markets
|
|
(1)
|
|
—
|
|
(2)
|
|
—
|
|
(2)
|
|
(5)
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Tissue
|
|
—
|
|
—
|
|
(1)
|
|
(2)
|
|
—
|
|
(3)
|
|
(1)
|
North
America
|
|
(1)
|
|
—
|
|
2
|
|
—
|
|
—
|
|
1
|
|
1
|
D&E
Markets
|
|
(2)
|
|
—
|
|
(3)
|
|
(9)
|
|
(1)
|
|
(15)
|
|
(6)
|
Developed
Markets
|
|
3
|
|
—
|
|
(5)
|
|
—
|
|
—
|
|
(2)
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
K-C Professional
|
|
(1)
|
|
1
|
|
—
|
|
(4)
|
|
(2)
|
|
(6)
|
|
—
|
North
America
|
|
(3)
|
|
—
|
|
—
|
|
(3)
|
|
—
|
|
(5)
|
|
(3)
|
D&E
Markets
|
|
—
|
|
1
|
|
11
|
|
(11)
|
|
(11)
|
|
(10)
|
|
13
|
Developed
Markets
|
|
4
|
|
1
|
|
(7)
|
|
(2)
|
|
(1)
|
|
(5)
|
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
|
|
1
|
|
1
|
|
2
|
|
(1)
|
|
(4)
|
|
(2)
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Impact of the sale of
the Brazil tissue and K-C Professional business, sale of the
PPE business and other exited businesses and markets in conjunction
with the 2024 Transformation Initiative.
|
(b)
|
Total may not equal the
sum of volume, mix/other, net price, divestitures and business
exits and currency due to rounding and excludes
intergeographic sales.
|
(c)
|
Combined impact of
changes in volume, mix/other and net price excluding prior year's
impact of divestitures and business exits.
|
|
|
Personal Care Segment
Personal Care sales of $2.6
billion decreased 2 percent in the quarter, while organic
sales increased 3 percent from a combination of pricing actions in
hyperinflationary economies as well as mix gains while volume was
in line with year ago across all markets. Product innovation and
solid commercial execution resulted in Baby and Child Care gaining
global weighted market share on a year-to-date basis.
Third quarter operating profit of $482
million decreased 4 percent driven by a step up in
advertising investment partially offset by optimization in
overheads while gross profit was broadly in line with year ago.
Consumer Tissue Segment
Consumer Tissue sales of $1.5
billion decreased 2 percent, with a decline in organic sales
of 1 percent. Organic decline was driven by retailer inventory
reductions in North America as
well as expected lower pricing in Western
Europe due to lapping of temporary pricing related to energy
surcharges in the prior year period.
Third quarter operating profit of $265
million decreased 1 percent, with gross productivity gains
offset by higher manufacturing costs and increased advertising
levels.
K-C Professional (KCP) Segment
KCP sales of $767 million
decreased 10 percent due to divestitures and business exits as well
as unfavorable currency impacts. Organic sales decreased 1 percent
driven by 1 percent unfavorable price impact due to lapping of
energy surcharges in Western
Europe.
Third quarter operating profit of $161
million decreased 4 percent primarily impacted by the
divestiture of the PPE business, underlying operating profit
benefited from productivity gains partially offset by volume
softness.
Cash Flow and Balance Sheet
Year-to-date cash provided by operations was $2.4 billion compared to $2.3 billion last year driven primarily by
stronger operating results. Year-to-date capital spending was
$512 million compared to
$549 million last year. The company returned $2.0 billion to shareholders through dividends
and repurchases of common stock. Total debt was $7.5 billion as of September 30, 2024, down from $8.0 billion as of December 31, 2023.
2024 Outlook
Based on its year-to-date results, the company has updated its
2024 outlook, with all factors compared to 2023, as follows:
Organic Net Sales are expected to grow between 3%-4%
versus a mid-single digit rate previously, primarily reflecting
discrete headwinds from changes in retail inventory levels.
Reported Net Sales are still expected to be negatively
impacted by 400 basis points of currency translation and 120 basis
points from divestitures.
Adjusted Operating Profit and Adjusted Earnings
Per Share are still expected to grow at a mid-to-high teens
percentage rate on a constant-currency basis.
Reported Operating Profit and Reported Earnings Per
Share are now expected to be negatively impacted by
approximately 650 basis points from currency translation versus a
previous expectation of 700 basis points.
This outlook reflects assumptions subject to change given the
macro environment.
Supplemental Materials and Live Webcast
Supplemental materials will be available at approximately
6:35 a.m. Eastern Daylight Time in
the Investor Relations section of www.kimberly-clark.com. The
company will host a live Q&A session with investors and
analysts on October 22, 2024, at
8:00 a.m. Eastern Daylight Time. The
supplemental materials and Kimberly-Clark's Q&A session can be
accessed at investor.kimberly-clark.com. A replay of the webcast
will be available following the event through the same website.
About Kimberly-Clark
Kimberly-Clark (NYSE: KMB) and its trusted brands are an
indispensable part of life for people in more than 175 countries
and territories. Fueled by ingenuity, creativity, and an
understanding of people's most essential needs, we create products
that help individuals experience more of what's important to them.
Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex,
Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus,
Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2
share positions in approximately 70 countries. We use sustainable
practices that support a healthy planet, build strong communities,
and ensure our business thrives for decades to come. We are proud
to be recognized as one of the World's Most Ethical
Companies(R) by Ethisphere for the fifth year in a row.
To keep up with the latest news and to learn more about the
company's 150-year history of innovation, visit
kimberly-clark.com.
Copies of Kimberly-Clark's Annual Report to Stockholders and its
proxy statements and other SEC filings, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K, are made available free of charge on the company's
website on the same day they are filed with the SEC. To view these
filings, visit the Investors section of the company's website.
Forward Looking Statements
Certain matters contained in this news release concerning the
business outlook, including raw material, energy and other input
costs, the anticipated charges and savings from the 2024
Transformation Initiative, cash flow and uses of cash, growth
initiatives, innovations, marketing and other spending, net sales,
anticipated currency rates and exchange risks, including the impact
in Argentina and Türkiye,
effective tax rate, contingencies and anticipated transactions of
Kimberly-Clark, including dividends, share repurchases and pension
contributions, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 and
are based upon management's expectations and beliefs concerning
future events impacting Kimberly-Clark. There can be no assurance
that these future events will occur as anticipated or that our
results will be as estimated. Forward-looking statements speak only
as of the date they were made, and we undertake no obligation to
publicly update them.
The assumptions used as a basis for the forward-looking
statements include many estimates that, among other things, depend
on the achievement of future cost savings and projected volume
increases. In addition, many factors outside our control, including
the risk that we are not able to realize the anticipated benefits
of the 2024 Transformation Initiative (including risks related to
disruptions to our business or operations or related to any delays
in implementation), war in Ukraine
(including the related responses of consumers, customers, and
suppliers and sanctions issued by the U.S., the European Union,
Russia or other countries),
pandemics, epidemics, fluctuations in foreign currency exchange
rates, the prices and availability of our raw materials, supply
chain disruptions, disruptions in the capital and credit markets,
counterparty defaults (including customers, suppliers and financial
institutions with which we do business), failure to realize the
expected benefits or synergies from our acquisition and disposition
activity, impairment of goodwill and intangible assets and our
projections of operating results and other factors that may affect
our impairment testing, changes in customer preferences, severe
weather conditions, regional instabilities and hostilities
(including the war in Israel),
government trade or similar regulatory actions, potential
competitive pressures on selling prices for our products, energy
costs, general economic and political conditions globally and in
the markets in which we do business, as well as our ability to
maintain key customer relationships, could affect the realization
of these estimates.
The factors described under Item 1A, "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31,
2023, or in our other SEC filings, among others, could cause our
future results to differ from those expressed in any
forward-looking statements made by us or on our behalf. Other
factors not presently known to us or that we presently consider
immaterial could also affect our business operations and financial
results.
Non-GAAP Financial Measures
This news release and the accompanying tables include the
following financial measures that have not been calculated in
accordance with accounting principles generally accepted in the
U.S., or GAAP, and are therefore referred to as non-GAAP financial
measures:
- Adjusted earnings and earnings per share
- Adjusted gross and operating profit
- Adjusted effective tax rate
These non-GAAP financial measures exclude the following items
for the relevant time periods as indicated in the accompanying
non-GAAP reconciliation tables:
- 2024 Transformation Initiative - In 2024, we initiated this
transformation initiative to improve our focus on growth and reduce
our structural cost base by reorganizing into three new business
segments, making the corporate and regional overhead cost
structures more efficient and optimizing our global supply chain.
Results in 2024 include charges related to this program.
- Sale of PPE business - In 2024, we recognized a gain
related to the sale of our PPE business.
- Impairment of intangible assets - In the third quarter of 2024
and the second quarter of 2023, we recognized charges related to
the impairment of certain intangible assets related to Softex
and Thinx.
- Sale of Brazil tissue
and K-C Professional business - In the second quarter of 2023,
we recognized a net benefit related to the sale of our Brazil tissue and K-C Professional
business.
- Pension settlements - In 2023, we recognized pension settlement
charges related to lump-sum distributions from pension plan assets
exceeding the total of annual service and interest costs resulting
in a recognition of deferred actuarial losses.
The income tax effect of these non-GAAP items is calculated
based upon the tax laws and statutory income tax rates applicable
in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
The impact of these non-GAAP items on the Company's effective tax
rate represents the difference in the effective tax rate calculated
with and without the non-GAAP adjustment on Income Before Income
Taxes and Equity Interests and Provision for income taxes.
The company provides these non-GAAP financial measures as
supplemental information to our GAAP financial measures. Management
and the company's Board of Directors use adjusted earnings,
adjusted earnings per share and adjusted gross and operating profit
to (a) evaluate the company's historical and prospective financial
performance and its performance relative to its competitors, (b)
allocate resources and (c) measure the operational performance of
the company's business units and their managers. Management also
believes that the use of an adjusted effective tax rate provides
improved insight into the tax effects of our ongoing business
operations.
Additionally, the Management Development and Compensation
Committee of the company's Board of Directors has used certain of
the non-GAAP financial measures when setting and assessing
achievement of incentive compensation goals. These goals are based,
in part, on the company's adjusted earnings per share.
Certain non-GAAP financial measures referenced in this news
release are presented on a forward-looking basis. Kimberly-Clark
does not provide a reconciliation of these forward-looking non-GAAP
financial measures to the most directly comparable GAAP financial
measures on a forward-looking basis because it is unable to predict
certain adjustment items without unreasonable effort. Please note
that these items could be material to Kimberly-Clark's results
calculated in accordance with GAAP.
This news release includes information regarding organic sales
growth, which describes the impact of changes in volume, net
selling prices and product mix excluding prior year's impact of
divestitures and business exits on net sales. Changes in foreign
currency exchange rates and divestitures and business exits also
impact the year-over-year change in net sales.
KIMBERLY-CLARK
CORPORATION
CONSOLIDATED STATEMENTS
OF INCOME
(Millions, except per
share amounts)
|
|
|
Three Months
Ended
September 30
|
|
|
|
2024
|
|
2023
|
|
Change
|
Net
Sales
|
$
4,952
|
|
$
5,132
|
|
-4 %
|
Cost of products
sold
|
3,168
|
|
3,294
|
|
-4 %
|
Gross
Profit
|
1,784
|
|
1,838
|
|
-3 %
|
Marketing, research
and general expenses
|
1,097
|
|
1,029
|
|
+7 %
|
Impairment of
intangible assets
|
97
|
|
—
|
|
N.M.
|
Other (income) and
expense, net
|
(564)
|
|
35
|
|
N.M.
|
Operating
Profit
|
1,154
|
|
774
|
|
+49 %
|
Nonoperating
expense
|
(15)
|
|
(20)
|
|
-25 %
|
Interest
income
|
18
|
|
18
|
|
— %
|
Interest
expense
|
(67)
|
|
(74)
|
|
-9 %
|
Income Before Income
Taxes and Equity Interests
|
1,090
|
|
698
|
|
+56 %
|
Provision for income
taxes
|
(223)
|
|
(157)
|
|
+42 %
|
Income Before Equity
Interests
|
867
|
|
541
|
|
+60 %
|
Share of net income of
equity companies
|
48
|
|
50
|
|
-4 %
|
Net
Income
|
915
|
|
591
|
|
+55 %
|
Net income
attributable to noncontrolling interests
|
(8)
|
|
(4)
|
|
+100 %
|
Net Income
Attributable to Kimberly-Clark Corporation
|
$
907
|
|
$
587
|
|
+55 %
|
|
|
|
|
|
|
Per Share
Basis
|
|
|
|
|
|
Net Income
Attributable to Kimberly-Clark Corporation
|
|
|
|
|
|
Basic
|
$
2.70
|
|
$
1.74
|
|
+55 %
|
Diluted
|
$
2.69
|
|
$
1.73
|
|
+55 %
|
|
|
|
|
|
|
Cash Dividends
Declared
|
$
1.22
|
|
$
1.18
|
|
+3 %
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares
Outstanding
|
September
30
|
|
|
|
2024
|
|
2023
|
|
|
Outstanding shares as
of
|
333.5
|
|
338.0
|
|
|
Average diluted shares
for three months ended
|
337.2
|
|
338.9
|
|
|
|
|
|
|
|
|
Unaudited
N.M. - Not Meaningful
|
KIMBERLY-CLARK
CORPORATION
CONSOLIDATED STATEMENTS
OF INCOME
(Millions, except per
share amounts)
|
|
|
Nine Months
Ended
September 30
|
|
|
|
2024
|
|
2023
|
|
Change
|
Net
Sales
|
$
15,130
|
|
$
15,461
|
|
-2 %
|
Cost of products
sold
|
9,625
|
|
10,166
|
|
-5 %
|
Gross
Profit
|
5,505
|
|
5,295
|
|
+4 %
|
Marketing, research
and general expenses
|
3,202
|
|
2,968
|
|
+8 %
|
Impairment of
intangible assets
|
97
|
|
658
|
|
-85 %
|
Other (income) and
expense, net
|
(456)
|
|
(5)
|
|
N.M.
|
Operating
Profit
|
2,662
|
|
1,674
|
|
+59 %
|
Nonoperating
expense
|
(45)
|
|
(78)
|
|
-42 %
|
Interest
income
|
37
|
|
34
|
|
+9 %
|
Interest
expense
|
(206)
|
|
(223)
|
|
-8 %
|
Income Before Income
Taxes and Equity Interests
|
2,448
|
|
1,407
|
|
+74 %
|
Provision for income
taxes
|
(494)
|
|
(298)
|
|
+66 %
|
Income Before Equity
Interests
|
1,954
|
|
1,109
|
|
+76 %
|
Share of net income of
equity companies
|
172
|
|
143
|
|
+20 %
|
Net
Income
|
2,126
|
|
1,252
|
|
+70 %
|
Net (income) loss
attributable to noncontrolling interests
|
(28)
|
|
3
|
|
N.M.
|
Net Income
Attributable to Kimberly-Clark Corporation
|
$
2,098
|
|
$
1,255
|
|
+67 %
|
|
|
|
|
|
|
Per Share
Basis
|
|
|
|
|
|
Net Income
Attributable to Kimberly-Clark Corporation
|
|
|
|
|
|
Basic
|
$
6.23
|
|
$
3.71
|
|
+68 %
|
Diluted
|
$
6.21
|
|
$
3.70
|
|
+68 %
|
|
|
|
|
|
|
Cash Dividends
Declared
|
$
3.66
|
|
$
3.54
|
|
+3 %
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares
Outstanding
|
September
30
|
|
|
|
2024
|
|
2023
|
|
|
Average diluted shares
for nine months ended
|
337.9
|
|
338.8
|
|
|
|
|
|
|
|
|
Unaudited
N.M. - Not Meaningful
|
KIMBERLY-CLARK
CORPORATION
NON-GAAP
RECONCILIATIONS
(Millions, except per
share amounts)
|
|
|
|
Three months ended
September 30, 2024
|
|
|
As
Reported
|
|
2024
Transformation
Initiative
|
|
Sale of PPE
Business
|
|
Impairment of
Intangible
Assets
|
|
As
Adjusted
Non-GAAP
|
Cost of products
sold
|
|
$
3,168
|
|
$
31
|
|
$
—
|
|
$
—
|
|
$ 3,137
|
Gross Profit
|
|
1,784
|
|
(31)
|
|
—
|
|
—
|
|
1,815
|
Marketing, research and
general expenses
|
|
1,097
|
|
93
|
|
1
|
|
—
|
|
1,003
|
Impairment of
intangible assets
|
|
97
|
|
—
|
|
—
|
|
97
|
|
—
|
Other (income) and
expense, net
|
|
(564)
|
|
—
|
|
(566)
|
|
—
|
|
2
|
Operating
Profit
|
|
1,154
|
|
(124)
|
|
565
|
|
(97)
|
|
810
|
Provision for income
taxes
|
|
(223)
|
|
18
|
|
(112)
|
|
40
|
|
(169)
|
Effective tax
rate
|
|
20.5 %
|
|
—
|
|
—
|
|
—
|
|
22.7 %
|
Net Income Attributable
to Kimberly-Clark Corporation
|
|
907
|
|
(106)
|
|
453
|
|
(57)
|
|
617
|
Diluted Earnings per
Share(a)
|
|
2.69
|
|
(0.31)
|
|
1.34
|
|
(0.17)
|
|
1.83
|
|
|
Three Months Ended
September 30, 2023
|
|
|
As
Reported
|
|
Pension
Settlements
|
|
As
Adjusted
Non-GAAP
|
Nonoperating
expense
|
|
$
(20)
|
|
$
(4)
|
|
$
(16)
|
Provision for income
taxes
|
|
(157)
|
|
1
|
|
(158)
|
Effective tax
rate
|
|
22.5 %
|
|
—
|
|
22.5 %
|
Net Income Attributable
to Kimberly-Clark Corporation
|
|
587
|
|
(3)
|
|
590
|
Diluted Earnings per
Share(a)
|
|
1.73
|
|
(0.01)
|
|
1.74
|
|
|
|
|
|
|
|
(a)
|
"As Adjusted Non-GAAP"
may not equal "As Reported" plus "Adjustments" as a result of
rounding.
|
|
|
KIMBERLY-CLARK
CORPORATION
NON-GAAP
RECONCILIATIONS
(Millions, except per
share amounts)
|
|
|
|
Nine Months Ended
September 30, 2024
|
|
|
As
Reported
|
|
2024
Transformation
Initiative
|
|
Sale of PPE
Business
|
|
Impairment of
Intangible
Assets
|
|
As
Adjusted
Non-GAAP
|
Cost of products
sold
|
|
$
9,625
|
|
$
76
|
|
$
—
|
|
$
—
|
|
$
9,549
|
Gross Profit
|
|
5,505
|
|
(76)
|
|
—
|
|
—
|
|
5,581
|
Marketing, research and
general expenses
|
|
3,202
|
|
208
|
|
1
|
|
—
|
|
2,993
|
Impairment of
intangible assets
|
|
97
|
|
—
|
|
—
|
|
97
|
|
—
|
Other (income) and
expense, net
|
|
(456)
|
|
75
|
|
(566)
|
|
—
|
|
35
|
Operating
Profit
|
|
2,662
|
|
(359)
|
|
565
|
|
(97)
|
|
2,553
|
Provision for income
taxes
|
|
(494)
|
|
102
|
|
(112)
|
|
40
|
|
(524)
|
Effective tax
rate
|
|
20.2 %
|
|
—
|
|
—
|
|
—
|
|
22.4 %
|
Net Income Attributable
to Kimberly-Clark
Corporation
|
|
2,098
|
|
(257)
|
|
453
|
|
(57)
|
|
1,959
|
Diluted Earnings per
Share(a)
|
|
6.21
|
|
(0.76)
|
|
1.34
|
|
(0.17)
|
|
5.80
|
|
|
Nine Months Ended
September 30, 2023
|
|
|
As
Reported
|
|
Sale of Brazil
Tissue and K-C
Professional
Business
|
|
Impairment of
Intangible
Assets
|
|
Pension
Settlements
|
|
As
Adjusted
Non-GAAP
|
Cost of products
sold
|
|
$ 10,166
|
|
$
15
|
|
$
—
|
|
$
—
|
|
$
10,151
|
Gross Profit
|
|
5,295
|
|
(15)
|
|
—
|
|
—
|
|
5,310
|
Marketing, research and
general expenses
|
|
2,968
|
|
15
|
|
—
|
|
—
|
|
2,953
|
Impairment of
intangible assets
|
|
658
|
|
—
|
|
658
|
|
—
|
|
—
|
Other (income) and
expense, net
|
|
(5)
|
|
(74)
|
|
—
|
|
—
|
|
69
|
Operating
Profit
|
|
1,674
|
|
44
|
|
(658)
|
|
—
|
|
2,288
|
Nonoperating
expense
|
|
(78)
|
|
—
|
|
—
|
|
(31)
|
|
(47)
|
Provision for income
taxes
|
|
(298)
|
|
(18)
|
|
175
|
|
8
|
|
(463)
|
Effective tax
rate
|
|
21.2 %
|
|
—
|
|
—
|
|
—
|
|
22.6 %
|
Net (income) loss
attributable to
noncontrolling interests
|
|
3
|
|
—
|
|
20
|
|
—
|
|
(17)
|
Net Income Attributable
to Kimberly-Clark
Corporation
|
|
1,255
|
|
26
|
|
(463)
|
|
(23)
|
|
1,715
|
Diluted Earnings per
Share(a)
|
|
3.70
|
|
0.08
|
|
(1.36)
|
|
(0.07)
|
|
5.06
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
"As Adjusted Non-GAAP"
may not equal "As Reported" plus "Adjustments" as a result of
rounding.
|
Non-GAAP financial measures are not meant to be considered in
isolation or as a substitute for the comparable GAAP measures, and
they should be read only in conjunction with the company's
consolidated financial statements prepared in accordance with
GAAP. There are limitations to these non-GAAP financial
measures because they are not prepared in accordance with GAAP and
may not be comparable to similarly titled measures of other
companies due to potential differences in methods of calculation
and items being excluded. The company compensates for these
limitations by using these non-GAAP financial measures as a
supplement to the GAAP measures and by providing reconciliations of
the non-GAAP and comparable GAAP financial measures.
KIMBERLY-CLARK
CORPORATION
CONSOLIDATED BALANCE
SHEETS
(Millions)
|
|
|
September 30,
2024
|
|
December 31,
2023
|
ASSETS
|
|
|
|
Current
Assets
|
|
|
|
Cash and cash
equivalents
|
$
1,111
|
|
$
1,093
|
Accounts receivable,
net
|
2,229
|
|
2,135
|
Inventories
|
1,937
|
|
1,955
|
Other current
assets
|
570
|
|
520
|
Total Current
Assets
|
5,847
|
|
5,703
|
Property, Plant and
Equipment, Net
|
7,703
|
|
7,913
|
Investments in
Equity Companies
|
362
|
|
306
|
Goodwill
|
2,058
|
|
2,085
|
Other Intangible
Assets, Net
|
97
|
|
197
|
Other
Assets
|
1,098
|
|
1,140
|
TOTAL
ASSETS
|
$
17,165
|
|
$
17,344
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
Current
Liabilities
|
|
|
|
Debt payable within
one year
|
$
569
|
|
$
567
|
Trade accounts
payable
|
3,643
|
|
3,653
|
Accrued expenses and
other current liabilities
|
2,449
|
|
2,316
|
Dividends
payable
|
405
|
|
394
|
Total Current
Liabilities
|
7,066
|
|
6,930
|
Long-Term
Debt
|
6,882
|
|
7,417
|
Noncurrent Employee
Benefits
|
641
|
|
669
|
Deferred Income
Taxes
|
355
|
|
374
|
Other
Liabilities
|
751
|
|
860
|
Redeemable Preferred
Securities of Subsidiaries
|
26
|
|
26
|
Stockholders'
Equity
|
|
|
|
Kimberly-Clark
Corporation
|
1,285
|
|
915
|
Noncontrolling
Interests
|
159
|
|
153
|
Total Stockholders'
Equity
|
1,444
|
|
1,068
|
TOTAL LIABILITIES
AND STOCKHOLDERS' EQUITY
|
$
17,165
|
|
$
17,344
|
|
KIMBERLY-CLARK
CORPORATION
CONSOLIDATED STATEMENTS
OF CASH FLOWS
(Millions)
|
|
|
|
Nine Months Ended
September 30
|
|
|
2024
|
|
2023
|
Operating
Activities
|
|
|
|
|
Net income
|
|
$
2,126
|
|
$
1,252
|
Depreciation and
amortization
|
|
564
|
|
566
|
Asset
impairments
|
|
114
|
|
676
|
Stock-based
compensation
|
|
110
|
|
131
|
Deferred income
taxes
|
|
(86)
|
|
(297)
|
Net (gains) losses on
asset and business dispositions
|
|
(474)
|
|
(77)
|
Equity companies'
earnings (in excess of) less than dividends paid
|
|
(93)
|
|
(74)
|
Operating working
capital
|
|
154
|
|
111
|
Postretirement
benefits
|
|
10
|
|
34
|
Other
|
|
(8)
|
|
5
|
Cash Provided by
Operations
|
|
2,417
|
|
2,327
|
Investing
Activities
|
|
|
|
|
Capital
spending
|
|
(512)
|
|
(549)
|
Proceeds from asset
and business dispositions
|
|
649
|
|
219
|
Investments in time
deposits
|
|
(456)
|
|
(545)
|
Maturities of time
deposits
|
|
428
|
|
605
|
Other
|
|
(15)
|
|
4
|
Cash Provided by
(Used for) Investing
|
|
94
|
|
(266)
|
Financing
Activities
|
|
|
|
|
Cash dividends
paid
|
|
(1,220)
|
|
(1,189)
|
Change in short-term
debt
|
|
2
|
|
(336)
|
Debt
proceeds
|
|
—
|
|
357
|
Debt
repayments
|
|
(554)
|
|
(350)
|
Proceeds from exercise
of stock options
|
|
128
|
|
97
|
Acquisitions of common
stock for the treasury
|
|
(752)
|
|
(95)
|
Cash paid for
redemption of common securities of Thinx
|
|
—
|
|
(48)
|
Cash dividends paid to
noncontrolling interests
|
|
(19)
|
|
(16)
|
Other
|
|
(65)
|
|
(40)
|
Cash Used for
Financing
|
|
(2,480)
|
|
(1,620)
|
Effect of Exchange
Rate Changes on Cash and Cash Equivalents
|
|
(13)
|
|
(54)
|
Change in Cash and
Cash Equivalents
|
|
18
|
|
387
|
Cash and Cash
Equivalents - Beginning of Period
|
|
1,093
|
|
427
|
Cash and Cash
Equivalents - End of Period
|
|
$
1,111
|
|
$
814
|
|
KIMBERLY-CLARK
CORPORATION
BUSINESS SEGMENT
RESULTS
(Millions)
|
|
|
|
Three Months
Ended
September 30
|
|
|
|
Nine Months
Ended
September 30
|
|
|
|
|
2024
|
|
2023
|
|
Change
|
|
2024
|
|
2023
|
|
Change
|
NET
SALES
|
|
|
|
|
|
|
|
|
|
|
|
|
Personal
Care
|
|
$
2,635
|
|
$
2,700
|
|
-2 %
|
|
$
8,040
|
|
$
8,089
|
|
-1 %
|
Consumer
Tissue
|
|
1,539
|
|
1,567
|
|
-2 %
|
|
4,624
|
|
4,750
|
|
-3 %
|
K-C
Professional
|
|
767
|
|
854
|
|
-10 %
|
|
2,431
|
|
2,588
|
|
-6 %
|
Corporate &
Other
|
|
11
|
|
11
|
|
N.M.
|
|
35
|
|
34
|
|
N.M.
|
TOTAL NET
SALES
|
|
$
4,952
|
|
$
5,132
|
|
-4 %
|
|
$
15,130
|
|
$
15,461
|
|
-2 %
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING
PROFIT
|
|
|
|
|
|
|
|
|
|
|
|
|
Personal
Care
|
|
$
482
|
|
$ 502
|
|
-4 %
|
|
$
1,567
|
|
$
1,461
|
|
+7 %
|
Consumer
Tissue
|
|
265
|
|
267
|
|
-1 %
|
|
800
|
|
707
|
|
+13 %
|
K-C
Professional
|
|
161
|
|
168
|
|
-4 %
|
|
535
|
|
514
|
|
+4 %
|
Corporate &
Other(a)
|
|
(318)
|
|
(128)
|
|
N.M.
|
|
(696)
|
|
(1,013)
|
|
N.M.
|
Other (income) and
expense, net(a)
|
|
(564)
|
|
35
|
|
N.M.
|
|
(456)
|
|
(5)
|
|
N.M.
|
TOTAL OPERATING
PROFIT
|
|
$
1,154
|
|
$ 774
|
|
+49 %
|
|
$
2,662
|
|
$
1,674
|
|
+59 %
|
|
(a)
|
Corporate & Other
and Other (income) and expense, net include income and expense not
associated with the ongoing operations of the business segments,
including adjustments as indicated in the
Non-GAAP Reconciliations.
|
|
|
Unaudited
N.M. - Not Meaningful
|
[KMB-F]
Logo
- https://mma.prnewswire.com/media/648588/Kimberly_Clark_v1_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/kimberly-clark-announces-third-quarter-2024-results-and-reaffirms-2024-profit-outlook-302282351.html
SOURCE Kimberly-Clark Corporation